Avanir Pharmaceuticals
30 Enterprise, Suite 200
Aliso Viejo, CA 92656
United States
Tel: 949-445-8599
Website: https://www.avanir.com/
Email: recruiting@avanir.com
About Avanir Pharmaceuticals
At Avanir, our passionate team of thinkers is working to alleviate the burdens of those affected by central nervous system (CNS) conditions.
Our mission is to deliver innovative CNS solutions to improve the lives of patients and their care communities. Every day, we bring a singular focus to the research and development of groundbreaking pharmaceutical treatments for people with central nervous system (CNS) conditions. We have a passion for patients, based on our own personal experiences. When combined with scientific ingenuity and a commitment to transparency, we offer real solutions to those we serve.
When there’s a patient, caregiver or provider in need — we’ll protect! When there’s a call for innovative treatment solutions — we’ll answer! When there’s a CNS case that seems unsolvable — we’ll challenge! It’s who we are — we’re fighters. It’s why we’re here. We are Avanir.
324 articles about Avanir Pharmaceuticals
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Avanir is developing its future leadership from within through a program it calls “Leading at Avanir,” which focuses on emotional intelligence and situational leadership components.
-
Avanir Joins Decentralized Trials & Research Alliance (DTRA) as a Founding Member to Advance Access to Clinical Trials
4/19/2021
Global Industry Coalition Aims to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research
-
Avanir Pharmaceuticals Named One of Orange County's Best Places to Work
10/30/2020
Avanir Pharmaceuticals, Inc., a pharmaceutical company committed to delivering innovative central nervous system (CNS) solutions, today announced its recognition as one of the 2020 Best Places to Work in Orange County—the only pharmaceutical company listed in the Orange County Business Journal's 2020 "Best Places to Work in Orange County" Large Employer Category.
-
University of California Irvine's Paul Merage School of Business Announces Avanir Pharmaceuticals CEO and CFO Join Advisory Board of Center for Health Care Management and Policy
6/16/2020
Avanir Pharmaceuticals, Inc. and The UCI Paul Merage School of Business are pleased to announce the appointment of two new executives to the School's Center for Health Care Management and Policy advisory board. Wa'el Hashad, president and CEO of Avanir Pharmaceuticals,
-
Avanir Pharmaceuticals and Alzheimer's Orange County Partner for 2019 Walk4ALZ and Run4ALZ to Fight Alzheimer's and Dementia
11/18/2019
On a beautiful Orange County morning, Avanir Pharmaceuticals, Inc. joined the nonprofit Alzheimer's Orange County to raise awareness and funds to fight Alzheimer's and dementia
-
Avanir Pharmaceuticals, Inc. to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia
11/12/2019
Avanir Pharmaceuticals, Inc. announced that it will continue the clinical development program of AVP-786 for the treatment of agitation in patients with Alzheimer's dementia.
-
At CNS Summit 2019, Signant Health to Host Spotlight Session including speakers from Karuna and Avanir to Discuss the Future of eCOA and Data Analytics to Improve the Patient Experience in Clinical Research
10/23/2019
Signant proud to take leadership role at 10th annual summit as key pioneers and thought leaders convene to advance the science and technology of CNS research
-
Avanir Pharmaceuticals Announces Resolution of Government Investigation
9/26/2019
Avanir Pharmaceuticals, Inc. announced that it has reached a resolution of civil, criminal, and administrative claims with the federal government and participating state authorities.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
3/25/2019
Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company's phase 3 clinical development program investigating the efficacy, safety and tolerability of AVP-786 for the treatment of moderate-to-severe agitation in patients with Alzheimer's dementia.
-
Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules
2/13/2019
Avanir Pharmaceuticals, Inc., an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd., has reached an agreement in principle to resolve an investigation by the United States Department of Justice related to certain of Avanir's sales and marketing practices for its product NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules prior to 2017.
-
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail®
12/11/2018
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.
-
BioSpace Movers and Shakers - Oct. 22
10/22/2018
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes. -
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
-
Avanir is under fire after CNN filed a report showing how the company paid 500 prescribers about $14M over three years for prescribers to tout the benefits of its leading CNS drug Nuedexta.
-
SoCal's Avanir Axes 11% of Workforce
12/6/2017
Avanir Pharmaceuticals will lay off 11 percent of its workforce by the end of January 2018 as part of a company restructuring. -
Vivek Ramaswamy's Urovant Sciences Taps Former AVANIR Exec As Its New CEO
9/18/2017
-
AVANIR Initiates Phase II Study To Evaluate AVP-786 For Treatment Of Neurobehavioral Disinhibition Associated With Traumatic Brain Injury
6/7/2017
-
AVANIR Appoints Richard Malamut, MD, As Senior Vice President, Research & Development, And Chief Medical Officer
11/29/2016